...
首页> 外文期刊>Research journal of pharmacy and technology >Studies on Oral Sustain Delivery of Cefixlme from Floating Matrix Tablets Formulation and In Vitro Evaluation
【24h】

Studies on Oral Sustain Delivery of Cefixlme from Floating Matrix Tablets Formulation and In Vitro Evaluation

机译:漂浮基质片剂对头孢克肟口服缓释的研究及体外评价

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The objective of the present study was to deyelop Cefixime gastroretentive floating matrix tablets for prolonged gastric retention time and thereby increased drug bioavailability. Cefixime is a third generation Cephalosporins antibiotic which is slowly and incompletely absorbed from the GIT, which resulting into the poor bioavailability 40-50%.The floating tablets were prepared by direct compression method, using polymers like SCMC, Carbopol 934P, and HPMC K100M in an effervescent system and polypropylene foam powder (Accurel) in low density system.The powder blends was subjected for pre-compression parameters and were within prescribed limits and indicated free flowing property .The prepared tablets were evaluated for post- compression parameters such as weight variation, thickness, friability, hardness, drag content, in vitro buoyancy studies and in vitro release studies in 0.1N HC1 (pH1.2) for 12 h. Among all the formulations (Fl to F12), formulation (F8) which showed the buoyancy lag time 52 Sec, remained buoyant for 12h and release of Cefixime sustained over 12h when compared to other formulations. The in vitro data is fitted into different Kinetics models. The optimized formulation F8 followed Zero order kinetics and best fitted Korsmeyer - Peppas model followed by non-fickian diffusion (n=0. 753). FTIR studies revealed that, there was no incompatibility of the drug with excipients used. The stability studies conducted as per the ICH guidelines at 40 +-2°C and 75 +-5% RH for 1 month and the optimized formulation (F8) showed no significant change in physical appearance, drug content, total buoyancy time and in vitro dissolution study after storage. From this study, it was concluded that, the formulation (F8) can be retained for a longer period of time in the stomach and provided prolong release of the drug, hence it may increase the therapeutic efficacy of the drug by increasing the bioavailability.
机译:本研究的目的是对头孢克肟胃滞性漂浮基质片剂进行去斑,以延长胃保留时间,从而增加药物的生物利用度。头孢克肟是第三代头孢菌素抗生素,其从GIT吸收缓慢且不完全,导致生物利用度降低40-50%。采用直接压片法,使用SCMC,Carbopol 934P和HPMC K100M等聚合物直接制备浮片低泡体系中的泡腾体系和聚丙烯泡沫粉末(Accurel)。对粉末混合物进行预压缩参数设置,并在规定的范围内显示自由流动性。对制得的片剂进行压缩后参数评估,例如重量变化,厚度,易碎性,硬度,阻力含量,0.1N HCl(pH1.2)中的体外浮力研究和体外释放研究12 h。在所有制剂(F1至F12)中,与其他制剂相比,显示出浮力滞后时间52秒的制剂(F8)保持浮力12h,并且头孢克肟的释放持续超过12h。体外数据适合不同的动力学模型。优化的配方F8遵循零级动力学和最佳拟合Korsmeyer-Peppas模型,然后进行非菲克扩散(n = 0.753)。 FTIR研究表明,该药物与所用赋形剂没有不相容性。根据ICH指南在40 + -2°C和75 + -5%RH下进行了1个月的稳定性研究,并且优化的制剂(F8)的物理外观,药物含量,总浮力时间和体外均无显着变化储存后的溶出度研究。从该研究得出的结论是,制剂(F8)可以在胃中保留更长的时间,并且可以延长药物的释放时间,因此可以通过提高生物利用度来提高药物的治疗功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号